Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
  1. Home
  3. Tirzepatide Shows Neuroprotective Effects Via Regulating Brain Glucose Metabolism In App/ps1 Mice.
  1. Home
  3. Tirzepatide Shows Neuroprotective Effects Via Regulating Brain Glucose Metabolism In App/ps1 Mice.

Related Experiment Video

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.6K

Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice.

Shaobin Yang1, Xiaoqian Zhao1, Yimeng Zhang1

  • 1College of Life Sciences, Northwest Normal University, Lanzhou, Gansu 730070, China.

Peptides
|July 13, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Tirzepatide, a dual GLP-1/GIP receptor agonist, shows neuroprotective effects in Alzheimer

Keywords:
Alzheimer's diseaseAstrocyteGlucose metabolismMitochondrial dysfunctionTirzepatide

More Related Videos

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
06:34

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells

Published on: October 9, 2017

9.1K
Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
06:14

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Published on: May 8, 2018

8.8K

Related Experiment Videos

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.6K
New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
06:34

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells

Published on: October 9, 2017

9.1K
Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
06:14

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Published on: May 8, 2018

8.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Metabolic Disorders

Background:

  • Alzheimer's disease (AD) is characterized by amyloid plaques and neuronal apoptosis.
  • The molecular mechanisms underlying AD and potential therapeutic interventions require further investigation.
  • Tirzepatide, a novel dual GLP-1 and GIP receptor agonist, has shown promise in ameliorating cognitive deficits in diabetic models.

Purpose of the Study:

  • To investigate the neuroprotective role and molecular mechanisms of tirzepatide in an Alzheimer's disease mouse model.
  • To explore tirzepatide's effects on amyloid pathology, neuronal apoptosis, and brain glucose metabolism.

Main Methods:

  • Administration of tirzepatide (10 nmol/kg, once-weekly) to APP/PS1 mice for 8 weeks.
  • Assessment of GLP-1 receptor (GLP-1R), GFAP protein expression, and amyloid plaques.
  • Evaluation of neuronal apoptosis, anxiety, and cognitive function.
  • Analysis of mRNA expression in the hypothalamus and cortex.
  • Investigation of energetic metabolism, reactive oxygen species (ROS), mitochondrial function, and ATP levels in astrocytes.

    • Main Results:

    • Tirzepatide significantly reduced GLP-1R, GFAP, and amyloid plaque levels in the cortex.
    • It lowered amyloid-beta (Aβ)-induced neuronal apoptosis but did not alter anxiety or cognitive function.
    • Tirzepatide decreased blood glucose levels and modulated hypothalamic gene expression (GLP-1R, SACF1, ATF4, Glu2A, Glu2B).
    • Increased expression of key glycolytic enzymes (glucose transporter 1, hexokinase, G6PD, PFK) in the cortex.
    • Improved energetic metabolism by regulating ROS production and mitochondrial membrane potential, mitigating Aβ-induced mitochondrial dysfunction and ATP depletion in astrocytes via GLP-1R.

    Conclusions:

    • Tirzepatide demonstrates neuroprotective effects in an AD mouse model by reducing amyloid pathology and neuronal apoptosis.
    • The drug modulates brain glucose metabolism and enhances astrocyte mitochondrial function through GLP-1R signaling.
    • These findings suggest tirzepatide's potential as a therapeutic strategy for Alzheimer's disease, targeting both metabolic and neurodegenerative pathways.